Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alina N. Egorova"'
Autor:
Andrey A. Ivashchenko, Valeria N. Azarova, Alina N. Egorova, Ruben N. Karapetian, Dmitry V. Kravchenko, Natalia V. Krivonos, Vladimir G. Loginov, Stanislav V. Poyarkov, Elena A. Merkulova, Olga S. Rosinkova, Nikolay P. Savchuk, Mikhail A. Topr, Elena N. Simakina, Elena V. Yakubova, Alexandre V. Ivachtchenko
Publikováno v:
Viruses, Vol 13, Iss 7, p 1253 (2021)
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Externí odkaz:
https://doaj.org/article/bdadf2eb06b245cbb92ee84869032a4d
Autor:
Natalya B. Zakharzhevskaya, Anna A. Vanyushkina, Ilya A. Altukhov, Aleksey L. Shavarda, Ivan O. Butenko, Daria V. Rakitina, Anastasia S. Nikitina, Aleksandr I. Manolov, Alina N. Egorova, Eugene E. Kulikov, Innokentii E. Vishnyakov, Gleb Y. Fisunov, Vadim M. Govorun
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-16 (2017)
Abstract Numerous studies are devoted to the intestinal microbiota and intercellular communication maintaining homeostasis. In this regard, vesicles secreted by bacteria represent one of the most popular topics for research. For example, the outer me
Externí odkaz:
https://doaj.org/article/0a3a1a392b52497794ce3934fcb2bbae
Autor:
Stanislav V Poyarkov, Natalia V Krivonos, Elena N Simakina, Olga S Rosinkova, Elena A. Merkulova, Nikolay Filippovich Savchuk, Dmitry V. Kravchenko, Alina N. Egorova, Valeria N Azarova, Elena V Yakubova, Ruben N. Karapetian, Alexandre V. Ivachtchenko, Mikhail A Topr, Andrey Alexandrovich Ivashchenko, Vladimir G Loginov
Publikováno v:
Viruses, Vol 13, Iss 1253, p 1253 (2021)
Viruses
Viruses
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Autor:
Elena A. Merkulova, Dmitriy S. Gorchakov, Oleg D. Mitkin, Nataliya A. Penchul, Alina N. Egorova, George E. Rupchev, Allan G. Beniashvily, Denis S. Burminskiy, Lala N. Kasimova, Ruben N. Karapetian, Natalia V. Vostokova, Lubov Y. Gluskina, Olga A. Bukhanovskaya, Margarita A. Morozova, Taissia A. Lepilkina, Dmitry V. Kravchenko, Andrey Alexandrovich Ivashchenko, Sergey S. Potanin, Alexandre V. Ivachtchenko
Publikováno v:
Journal of psychiatric research. 143
Generalized anxiety disorder (GAD) is associated with an imbalance in the functioning of the stimulating neurotransmitter systems in human's brain. We studied the safety and therapeutic efficacy of aviandr, the new noradrenergic and specific serotone
Autor:
Elena A Smolyarchuk, Natalia V. Vostokova, Andrew A. Blinow, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Nikolay Filippovich Savchuk, Tagir A. Sitdekov, Elena A. Merkulova, Kirill A. Dmitriev, Elena N Simakina, Elena P. Pavlikova, Valeria N Azarova, Natalia A. Papazova, Andrey Alexandrovich Ivashchenko, Alexandre V. Ivachtchenko, Alina N. Egorova, Nikita V. Lomakin, Dmitry V. Kravchenko, Alexey P. Ilin, Ivan G. Gordeev
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Autor:
Ivan G. Gordeev, Andrey Alexandrovich Ivashchenko, Alexey P. Ilin, Dmitry V. Kravchenko, Nikolay Filippovich Savchuk, Kirill A. Dmitriev, Nikita V. Lomakin, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Elena N Simakina, Elena A. Merkulova, Natalia V. Vostokova, Natalia A. Papazova, Elena A Smolyarchuk, Alexandre V. Ivachtchenko, Andrew A. Blinow, Elena P. Pavlikova, Tagir A. Sitdekov, Alina N. Egorova, Valeria N Azarova
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4c74b1b527e94b4d82f6b1475524f5